Safety and Efficacy Study in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2010-02-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The
safety and how well the body can handle the drug will also be investigated. The study will be
conducted in Russia in hospitalised patients with severe depression. GSK163090 will be
compared with placebo, which looks like the study drug but does not contain any active
substance. Subjects will be given either the study drug or the matching placebo.